Diversify Advisory Services LLC Has $1.22 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Diversify Advisory Services LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,769 shares of the company’s stock after purchasing an additional 221 shares during the period. Diversify Advisory Services LLC’s holdings in AstraZeneca were worth $1,219,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. McClarren Financial Advisors Inc. raised its position in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. acquired a new stake in AstraZeneca in the second quarter worth $26,000. Pathway Financial Advisers LLC acquired a new position in AstraZeneca during the 1st quarter worth approximately $29,000. RFP Financial Group LLC raised its position in shares of AstraZeneca by 56.3% during the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after purchasing an additional 178 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its holdings in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AZN. TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Down 1.0 %

Shares of NASDAQ AZN opened at $75.22 on Wednesday. The company has a market cap of $233.23 billion, a price-to-earnings ratio of 36.34, a PEG ratio of 1.39 and a beta of 0.46. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average is $80.03 and its 200 day moving average is $78.68. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.